|
AKIRIN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.54089999999152E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.67439999999264E-07 |
| Normal-vs-Stage2 |
3.119000E-01 |
| Normal-vs-Stage3 |
1.988880E-04 |
| Normal-vs-Stage4 |
1.3582000000234E-06 |
| Stage1-vs-Stage2 |
8.426300E-02 |
| Stage1-vs-Stage3 |
6.945200E-01 |
| Stage1-vs-Stage4 |
2.268800E-01 |
| Stage2-vs-Stage3 |
1.596850E-01 |
| Stage2-vs-Stage4 |
2.335700E-02 |
| Stage3-vs-Stage4 |
2.048800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.30130000506068E-08 |
| Normal-vs-AfricanAmerican |
3.502300E-03 |
| Normal-vs-Asian |
2.02569999996349E-06 |
| Caucasian-vs-AfricanAmerican |
6.927400E-01 |
| Caucasian-vs-Asian |
7.702800E-01 |
| AfricanAmerican-vs-Asian |
5.257000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.21219999999978E-05 |
| Normal-vs-Female |
1.54640000005202E-06 |
| Male-vs-Female |
9.097400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.65829999918688E-08 |
| Normal-vs-Age(41-60Yrs) |
6.01479999999821E-05 |
| Normal-vs-Age(61-80Yrs) |
1.562100E-02 |
| Normal-vs-Age(81-100Yrs) |
4.650600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.024040E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.900000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.710200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.550000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.533000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.400400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.376000E-01 |
| Classical-VS-Follicular |
9.99200722162641E-16 |
| Classical-VS-Other |
6.400200E-01 |
| Classical-VS-Normal |
1.44300016380328E-10 |
| Tall-VS-Follicular |
6.31749999999709E-05 |
| Tall-VS-Other |
6.134200E-01 |
| Tall-VS-Normal |
1.759180E-04 |
| Follicular-VS-Other |
6.055600E-03 |
| Follicular-VS-Normal |
1.869590E-01 |
| Other-VS-Normal |
1.024400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.363300E-03 |
| Normal-vs-N1 |
1.56319999999877E-05 |
| N0-vs-N1 |
1.732310E-02 |
|
|
